Emerging Markets Earnings Roundup: Pfizer, Merck, AbbVie (Part 4)
This article was originally published in PharmAsia News
Executive Summary
AbbVie, Merck and Pfizer had contrasting numbers for their third quarter earnings. While AbbVie rode high on Humira, Merck faced tough conditions in China and Mexico. Pfizer outclassed most global companies in China, with a growth of 8%, which could have doubled had it not transferred some products to its Chinese JV with Hisun.
You may also be interested in...
Divestiture Possible For Merck’s Animal Health, Consumer Units; Januvia’s Sales Slide
The performance of Merck’s diabetes franchise came under scrutiny by analysts on an earnings call Oct 28, after the company reported sales of its number one drug fell 5% in the third quarter year on year. Top executives came closer than ever to saying they are inclined to divest non-core businesses, including animal health.
AbbVie Pipeline Offers Multiple Means Of Protection Against Humira Sales Erosion
Hepatitis C combo is just one of AbbVie’s late-stage pipeline prospects to cover losses from generic competition to TriCor/Trilipix and the threat of biosimilar competition to Humira. It also has ABT-199, daclizumab and elagolix in Phase III studies.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.